HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $22 price target.